Ultrasound contrast developer Acusphere said that its Imagify contrast agent will be reviewed during a planned public meeting of the U.S. Food and Drug Administration (FDA)'s Cardiovascular and Renal Drugs Advisory Committee on December 10.
Imagify has a proposed indication for patients with stable chest pain being evaluated for inducible ischemia for the detection of coronary artery disease based on assessment of myocardial perfusion and wall motion, according to the Watertown, MA-based firm.
Related Reading
Acusphere taps new VP, September 25, 2008
Acusphere receives Nasdaq noncompliance notice, August 14, 2008
Acusphere reports Q2 results, August 12, 2008
Acusphere cuts staff, July 29, 2008
Acusphere gets Nasdaq warning letter, July 15, 2008
Copyright © 2008 AuntMinnie.com